Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Effekt af erythropoietin (EPO) på kognitiv funktion og frontallapsaktivitet hos patienter med bipolar sygdom eller depression i remission med kognitive vanskeligheder (PRETEC-EPO)

Projekt: Typer af projekterProjekt

Vis graf over relationer
Prefrontal Target Engagement as a biomarker model for Cognitive improvement: EPO (2016-Present). There are no valid and reliable biomarkers for pro-cognitive efficacy to select among new candidate cognition treatments prior to large-scale clinical efficacy trials. This study investigates whether the multifunctional body-own protein erythropoietin (EPO) improves cognitive function and enhances neural activity in the dorsolateral prefrontal cortex in patients with affective disorders. If so, this would be an important step toward validation of a putative neurocircuitry-based biomarker model of pro-cognitive efficacy.

Randomised, controlled, double-blind trial investigating the effects of 12 weeks of weekly EPO/ saline infusions. Participants were assessed for neuropsychological function, mood symptoms, psychosocial functions 4 times (baseline, after 2 weeks of treatment, after treatment completion and 6 months follow-up) and with fMRI at baseline and after 2 weeks of treatment. Blood tests are taken and medical examinations are conducted at a weekly basis to ensure participant safety (13 blood tests in total).

Resultater (forventede):
The study is underway with expected completion in September 2021.

Diskussion/Impact (forventet):
If this trial reveals pro-cognitive effects of EPO, this may influence future treatment of mood disorders and/or preventive strategies in at-risk populations. The fMRI analyses may unravel key neurobiological targets for pro-cognitive treatment,


  • Sundhedsvidenskab - Mood Disorders, Neuroimaging, Biomarkers, Pharmacology, Psychological assessment and psychometrics, Cognition, Randomized Controlled Clinical Trial

ID: 61736728